News

5

minute read

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval

The financing is one of the largest Series A rounds ever in Europe for a medical technology company and was led by New Enterprise Associates (NEA) as part of a syndicate of new investors F-Prime Capital, Lightstone Ventures, and Intuitive Ventures, alongside existing investors Oxford Science Enterprises (OSE) and 8VC.
5

minute read

Successful first-in-human implants of Amber-UI: an intelligent, closed-loop bioelectrical therapy for urge and mixed urinary incontinence

Ground-breaking clinical study (AURA-2) will evaluate safety and pilot efficacy of Amber-UI to treat urge and mixed urinary incontinence. Early data confirm feasibility of surgical procedure and therapy, with full read out expected later in 2023.
3

minute read

Amber Tx acquires Bioinduction Limited and its Picostim DyNeuMo platform

Amber is using the platform to explore a closed-loop therapy for mixed urinary incontinence (Amber-UI). The acquisition supports the Company’s strategy to develop intelligent, transformative neuromodulation therapies for patients with functional disorders of the nervous system. Financial details are not disclosed.
4

minute read

Positive preliminary results from first-in-human investigation of Amber-UI

Amber Therapeutics, an innovative medical technology company developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system, announces the presentation of the first data from its AURA-2 (Augmenting Urinary Reflex Activity) first-in-human study evaluating Amber-UI.